clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Hardy DJ et al. | Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. | 1992 | Diagn. Microbiol. Infect. Dis. | pmid:1530914 |
Chu S et al. | Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. | 1992 | J Clin Pharmacol | pmid:1531484 |
Heifets LB et al. | Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. | 1992 | Am. Rev. Respir. Dis. | pmid:1532486 |
Guay DR and Craft JC | Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis. | 1992 | J. Intern. Med. | pmid:1532615 |
Ruf B et al. | Failure of clarithromycin in preventing toxoplasmic encephalitis in AIDS patients. | 1992 | J. Acquir. Immune Defic. Syndr. | pmid:1532831 |
Cynamon MH and Klemens SP | Activity of azithromycin against Mycobacterium avium infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1329622 |
Chonmaitree T et al. | Effect of viral respiratory tract infection on outcome of acute otitis media. | 1992 | J. Pediatr. | pmid:1534364 |
Knothe H | [Short-term therapy of acute respiratory and ORL infections with Clarithromycin]. | 1992 | Z Gesamte Inn Med | pmid:9022402 |
Bale MJ et al. | MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. | 1992 | J. Clin. Microbiol. | pmid:1310329 |
Neu HC | New macrolide antibiotics: azithromycin and clarithromycin. | 1992 | Ann. Intern. Med. | pmid:1310839 |
Brown BA et al. | Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. | 1992 | Antimicrob. Agents Chemother. | pmid:1317144 |
Bahal N and Nahata MC | The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. | 1992 | Ann Pharmacother | pmid:1318761 |
Chu SY et al. | Absolute bioavailability of clarithromycin after oral administration in humans. | 1992 | Antimicrob. Agents Chemother. | pmid:1387301 |
Yajko DM et al. | Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. | 1992 | Antimicrob. Agents Chemother. | pmid:1387302 |
Cohen Y et al. | Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. | 1992 | Antimicrob. Agents Chemother. | pmid:1332586 |
Sifrim D et al. | Comparison of the effects of midecamycin acetate and clarithromycin on gastrointestinal motility in man. | 1992 | Drugs Exp Clin Res | pmid:1292916 |
Dautzenberg B | [Treatment of atypical mycobacterium infections: current state and therapeutic perspectives]. | 1992 | Rev Pneumol Clin | pmid:1296257 |
Peters DH and Clissold SP | Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. | 1992 | Drugs | pmid:1379907 |
Yajko DM | In vitro activity of antimicrobial agents against the Mycobacterium avium complex inside macrophages from HIV1-infected individuals: the link to clinical response to treatment? | 1992 | Res. Microbiol. | pmid:1455069 |
Rastogi N and Goh KS | Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. | 1992 | Antimicrob. Agents Chemother. | pmid:1482156 |
Rastogi N et al. | Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. | 1992 | Antimicrob. Agents Chemother. | pmid:1482157 |
Derouin F et al. | Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1482160 |
Takeda H et al. | [A study to clarify the mechanism of the usefulness of the macrolides--the influence of clarithromycin to biofilm with P. aeruginosa]. | 1992 | Kansenshogaku Zasshi | pmid:1363435 |
Rehg JE | Anti-cryptosporidial activity of macrolides in immunosuppressed rats. | 1991 Nov-Dec | J. Protozool. | pmid:1667930 |
Hughes WT | Macrolide-antifol synergism in anti-Pneumocystis carinii therapeutics. | 1991 Nov-Dec | J. Protozool. | pmid:1818149 |
De Punzio C et al. | Isolation of Chlamydia trachomatis during IVF-ET. | 1991 Jul-Aug | Acta Eur. Fertil. | pmid:1844324 |
Cogo R et al. | [Dynamics of sIgA concentration in bronchial secretions in patients with COBP treated with clarithromycin]. | 1991 Jan-Dec | G Ital Chemioter | pmid:1365564 |
Anderson G | Clarithromycin in the treatment of community-acquired lower respiratory tract infections. | 1991 | J. Hosp. Infect. | pmid:1684979 |
Davey PG | The pharmacokinetics of clarithromycin and its 14-OH metabolite. | 1991 | J. Hosp. Infect. | pmid:1684980 |
King A and Phillips I | A comparison of the in-vitro activity of clarithromycin, a new macrolide antibiotic, with erythromycin and other oral agents. | 1991 | J. Hosp. Infect. | pmid:1684981 |
Wood MJ | The tolerance and toxicity of clarithromycin. | 1991 | J. Hosp. Infect. | pmid:1684982 |
Clarithro- and azithromycin--better erythromycins? | 1991 | Drug Ther Bull | pmid:1665125 | |
Rastogi N et al. | Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1667250 |
Gu JW et al. | Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens. | 1991 | J Clin Pharmacol | pmid:1837032 |
Hughes WT and Killmar JT | Synergistic anti-Pneumocystis carinii effects of erythromycin and sulfisoxazole. | 1991 | J. Acquir. Immune Defic. Syndr. | pmid:2016690 |
Rastogi N and Labrousse V | Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1828135 |
Ji B et al. | Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1828136 |
Lu MY et al. | A polymer carrier system for taste masking of macrolide antibiotics. | 1991 | Pharm. Res. | pmid:1829521 |
Perronne C et al. | Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1656860 |
Morgan DK et al. | A reversed-phase high-performance liquid chromatographic method for the determination and identification of clarithromycin as the drug substance and in various dosage forms. | 1991 | J Pharm Biomed Anal | pmid:1831386 |
Dautzenberg B et al. | Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. | 1991 | Am. Rev. Respir. Dis. | pmid:1832527 |
Rotsch TD et al. | Determination of clarithromycin as a contaminant on surfaces by high-performance liquid chromatography using electrochemical detection. | 1991 | Pharm. Res. | pmid:1833731 |
Jorgensen JH et al. | Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. | 1991 | Antimicrob. Agents Chemother. | pmid:1834012 |
Truffot-Pernot C et al. | Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1834015 |
Hamedani P et al. | The safety and efficacy of clarithromycin in patients with Legionella pneumonia. | 1991 | Chest | pmid:1835689 |
Fernandez-Martin J et al. | Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. | 1991 | Antimicrob. Agents Chemother. | pmid:1836943 |
Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
Straneo G and Scarpazza G | Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. | 1990 Mar-Apr | J. Int. Med. Res. | pmid:2140330 |
Fraschini F | Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. | 1990 Mar-Apr | J. Int. Med. Res. | pmid:2140331 |
Ferrero JL et al. | Metabolism and disposition of clarithromycin in man. | 1990 Jul-Aug | Drug Metab. Dispos. | pmid:1976065 |